Date: 2012-01-09
Type of information:
Compound: compounds and companion diagnostics for the potential treatment of pain
Company: Xenon Pharmaceuticals (USA) Genentech, a member of the Roche Group (USA - Switzerland)
Therapeutic area: CNS diseases
Type agreement:
Action mechanism:
Disease: pain
Details: Xenon Pharmaceuticals has announced a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain. Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain. Under the terms of the agreement, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products.
Financial terms: Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications. In addition, Xenon will receive royalties on sales of products resulting from the collaboration.
Latest news:
